Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-28
2006-11-28
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600
Reexamination Certificate
active
07141545
ABSTRACT:
A method for treating mammalian articular cartilage disorders, more particularly osteoarthritis, and trauma-related cartilage injuries using insulin-like growth factor I (IGF-I) is provided. The method comprises increasing the amount of IGF-I at the diseased or injured articular site to a therapeutically effective level that is capable of maintenance and/or regeneration of cartilage, which is beneficial to the long-term treatment of osteoarthritis and trauma-related injuries to cartilage tissues. In one embodiment of the invention, single doses of at least 0.01 mg of pharmaceutically effective IGF-I are administered intermittently such that the duration of time off of therapy is greater than the time on therapy, more preferably with a frequency of administration of about once per week or less.
REFERENCES:
patent: 4642120 (1987-02-01), Nevo et al.
patent: 5206023 (1993-04-01), Hunziker
patent: 5374620 (1994-12-01), Clark et al.
patent: 5407913 (1995-04-01), Sommer et al.
patent: 5444047 (1995-08-01), DiPasquale
patent: 5597802 (1997-01-01), Clark et al.
patent: 5643867 (1997-07-01), Maack et al.
patent: 5655546 (1997-08-01), Halpern
patent: 5712249 (1998-01-01), Halloran
patent: 5728676 (1998-03-01), Halloran
patent: 5843899 (1998-12-01), Halloran
patent: 5853746 (1998-12-01), Hunziker
patent: 5942499 (1999-08-01), Radomsky
patent: 6645945 (2003-11-01), Radomsky et al.
patent: 0 434 625 (1995-04-01), None
patent: 0 742 228 (1996-11-01), None
patent: 2268190 (1990-11-01), None
patent: 6312931 (1994-11-01), None
patent: WO 92/13565 (1992-08-01), None
patent: WO 94/12219 (1994-06-01), None
patent: WO 95/32003 (1995-11-01), None
patent: WO 96/02565 (1996-02-01), None
patent: WO 96/07424 (1996-03-01), None
patent: WO 96/37216 (1996-11-01), None
patent: WO 98/00183 (1998-01-01), None
patent: WO 99/08728 (1999-02-01), None
patent: WO 99/24062 (1999-05-01), None
Caldwell et al., “A Safety Tolerability and Pharmacokinetic Study of Intra-Articular Recombinant Human Insulin-Like Growth Factor (rhIGF-I) in Patients with Severe Osteoarthritis (OA) of the Knee,” Abstract 941, Abstract Supplement 2000, American College of Rheumatology 64thAnnual Scientific Meeting and Association of Rheumatology Health Professionals 35thAnnual Scientific Meeting, Oct. 29-Nov. 2, 2000, Philadelphia, Pennsylvania, p. S223, American College of Rheumatology, Atlanta, Georgia.
Chen et al., “Pharmacokinetics of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I) and a Slow-Release Formulation of rhIGF-I in a Dog Model of Osteoarthritis,” Abstract 3390, American Association of Pharmaceutical Scientists Annual Meeting, Nov. 15-18, 1998, San Francisco, California.
Chevalier et al., “Production of Binding Proteins and Role of the Insulin-Like Growth Factor 1 Binding Protein 3 in Human Articular Cartilage Explants,”British Journal of Rheumatology, 1996, pp. 515-522, vol. 35, British Society for Rheumatology.
Chiron News, “Chiron Concludes rhIGF-I Osteoarthritis Clinical Development Program,” Press Release, Jul. 25, 2000.
Doré et al., “Human Osteoarthritic Chondrocytes Possess an Increased Number of Insulin-Like Growth Factor 1 Binding Sites But Are Unresponsive to Its Stimulation,”Arthritis and Rheumatism, 1994, pp. 253-263, vol. 37(2), American College of Rheumatology, USA.
Fernihough et al., “Local Disruption of the Insulin-Like Growth Factor System in the Arthritic Joint,”Arthritis and Rheumatism, Sep. 1996, pp. 1556-1565, vol. 39(9), American College of Rheumatology, USA.
Frisbie et al., “Insulin-Like Growth Factor 1 and Corticosteroid Modulation of Chondrocyte Metabolic and Mitogenic Activities in Interleukin 1-Conditioned Equine Cartilage,”American Journal of Veterinary Research, 1997, pp. 524-530, vol. 58(5), College of Veterinary Medicine, Cornell University, USA.
Guler et al., “Recombinant Human Insulin-Like Growth Factor 1 Stimulates Growth and Has Distinct Effects on Organ Size in Hypophysectomized Rats,”Proceedings of the National Academy of Sciences of the USA,1988, pp. 4889-4893, vol. 85, Medical Sciences, Zurich, Switzerland.
Lloyd et al., “Relation Between Insulin-Like Growth Factor-1 Concentrations, Osteoarthritis, Bone Density, and Fractures in the General Population: The Chingford Study,”Annals of the Rheumatic Diseases,1996, pp. 870-874, vol. 55, Extended Reports.
McAlindon et al., “Levels of Insulin Related Growth Factor 1 in Osteoarthritis of the Knee,”Annals of the Rheumatic Diseases, 1993, pp. 229-231, vol. 52.
Ramanathan-Girish et al., “Joint Tissue Distribution in Dogs Following Intraarticular (IA) Administration of Recombinant Human Insulin-Like Growth Factor (rhIGF-I),” Absrtract T3416, American Association of Pharmaceutical Scientists Annual Meeting and Exposition, Oct. 21-25, 2001, Denver, Colorado.
Rogachefsky et al., “Treatment of Canine Osteoarthritis with Insulin-Like Growth Factor-1 (IGF-I) and Sodium Pentosan Polysulfate,”Osteoarthritis and Cartilage,1993, pp. 105-114, vol. 1.
Trippel, “Growth Factor Actions on Articular Cartilage,”Journal of Rheumatology,Feb. 1995, pp. 129-132, vol. 22, Supplement 43.
van Beuningen et al., “Insulin-Like Growth Factor Stimulation of Articular Chondrocyte Proteoglycan Synthesis. Availability and Responses at Different Ages,”British Journal of Rheumatology,1993, pp. 1037-10430, vol. 32, British Society for Rheumatology.
Wolfgang et al., “Efficacy and Safety of Recombinant Human Insulin-Like Growth Factor (rhIGF-I) in a Canine Model of Osteoarthritis,” Abstract B15, Society of Toxicologists Annual Meeting, Mar. 1999, New Orleans, Louisiana.
Chen Sharon A.
Guler Hans-Peter
Owen Ralph M.
Pike Marilyn C.
Seely Lynn B.
Abrahamson Susan
Borin Michael
Harbin Alisa A.
Henry Leslie T.
Novartis Vaccines and Diagnostics Inc.
LandOfFree
Compositions and methods for treating articular cartilage... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating articular cartilage..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating articular cartilage... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3688908